Sirios Capital Management L P Purchases Shares of 19,796 Kenvue Inc. (NYSE:KVUE)

Sirios Capital Management L P bought a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 19,796 shares of the company's stock, valued at approximately $423,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Grove Bank & Trust lifted its stake in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue during the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. boosted its position in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after buying an additional 571 shares during the period. Fortitude Family Office LLC grew its stake in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc raised its stake in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after acquiring an additional 1,441 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of KVUE stock opened at $23.19 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market cap of $44.49 billion, a PE ratio of 43.75, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a fifty day moving average price of $22.97 and a 200 day moving average price of $22.41.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.54%. Kenvue's dividend payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Redburn Atlantic began coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Citigroup lifted their price target on shares of Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a research note on Monday, April 14th. Canaccord Genuity Group boosted their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Piper Sandler raised their price target on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Finally, Evercore ISI initiated coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.